Compare stocks

Formycon AG is a biotechnology company based in Planegg, Germany, specializing in the development of biosimilar products. The company focuses primarily on creating biosimilar versions of top-selling biopharmaceuticals, addressing fields such as ophthalmology and immunology. Known for its significant expertise in protein and biopharmaceutical development, Formycon leverages its proprietary technical platform to advance its biosimilar pipeline. The company's strategic positioning includes partnerships with other pharmaceutical firms to co-develop and commercialize its biosimilar candidates. Formycon's competitive strength lies in its robust development capabilities and focus on high-growth therapeutic areas.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.